Breaking News

Glenmark Pharma Appoints President North America

December 2, 2013

Gioia brings 25 years of industry experience

Philip Andrew Gioia has been appointed president North America and Global API business at Glenmark Pharmaceuticals. Mr. Gioia will be responsible for the generics and branded business across North America and also Global API sales and marketing. Mr. Gioia will be based in Mahwah, NJ and will report to Glenn Saldanha, chairman and managing director. He brings more than 25 years of experience in the U.S. pharmaceutical industry.
 
Mr. Gioia joins the company from Bausch & Lomb (acquired by Valeant Pharmaceuticals), where he most recently served as global head of diversified products and business development, Pharmaceuticals. Prior to that, he was division head of the Pharmaceutical Business Unit, North America, responsible for all aspects of P&L management, in addition to overall strategic commercial operations for the brand, generic and OTC divisions.
 
Prior to Bausch & Lomb, he spent 13 years at Barr Pharmaceuticals in roles of increased responsibility, including vice president and senior vice president of sales, and senior vice president of the $1.6 billion U.S. Generic Sales & Marketing business. He also led the forecasting group and was involved in product selection, planning, and logistics.

Related Packaging:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision